Ellen Cappellino
SVP, Market Access & Patient Services
Expertise:
As a proven expert in market access, Ellen Cappellino is helping EVERSANA quickly and safely deliver new treatments into the hands of the physicians and patients who will benefit from them. Ellen’s broad commercial background and extensive experience leading market access strategy and teams spans across large global and emerging biopharmaceutical companies. Now she’s leveraging her expertise to guide EVERSANA’s clients as they navigate the complex healthcare landscape with our top goal in mind – improving and transforming the patient journey.
Ellen holds an MBA from New York University and a BS from Albany College of Pharmacy and Health Sciences.
Articles by Ellen Cappellino
New Legislation Supports Payment for Digital Therapeutics
Earlier this month, the Access to Digital Prescription Therapeutics Act of 2022 was introduced by Rep. Mike Thompson (D-CA) to the U.S. House of Representatives as H.R. 7051 and by Sen. Shelley Moore Capito (R-WV) to the U.S. Senate as S. 3791. This precedent-setting legislation demonstrates the bicameral, bipartisan commitment to promoting the use of […]
Prescription Digital Therapeutics Coding: A Good First Step by CMS
The Centers for Medicare and Medicaid Services (CMS) recently issued a new code under the Healthcare Common Procedural Coding System (HCPCS) regarding prescription digital therapeutics (PDTs). These types of therapies are generally app- or device-based and can be used in any therapeutic category. This is certainly an exciting development for the PDT sector, as many […]
Reversing the Complexity of Oncology Commercialization: How to solve for launch challenges in a chaotic ecosystem
As physicians, patients and caregivers tirelessly fight complex diseases, a growing number of drug manufacturers are preparing to launch new oncology therapies. These high-science therapies are entering the market at rapid rates: Presently, there are 500 active cell and gene therapy agents in clinical development, with a great momentum building for immuno-oncology treatments. The Oncology […]
Telling the Whole Story: An Integrated Approach to Value Proposition Creation
Market shifts are underway, emphasizing the need for value propositions that are more seamless and integrated across functions. Adapting to these changes will be critical if manufacturers want to maximize pricing opportunities and avoid missing opportunities to generate data to demonstrate their product’s value effectively with different audiences. The most robust value propositions require expertise […]
Fearless in Pharma: Addressing Unmet Medical Needs Through Bold Innovation
5,789 new oncology products are currently in development, with 3,677 in phases I and II. Science continues to evolve and provide more patients life-changing therapies, but the commercialization model of these new therapies has not changed in decades – until now. Innovation demands disruptive thinking, and our experts agree. EVERSANA’s Ellen Cappellino sat down with […]
PharmaVOICE Webinar: Next Gen Commercialization Model for Oncology
In a new 60-minute virtual panel, “Next Gen Commercial Models in Oncology,” PharmaVOICE Editor Taren Grom sat down with industry leaders to discuss how changing market dynamics and a rich pipeline in oncology are creating a need for next gen commercial models.